Objective: To evaluate the usefulness of propofol as an alternative drug to amobarbital for the Wada test. Methods: The authors analyzed 67 right-handed patients out of 123 patients who were candidates for neurosurgical therapy and thus underwent the Wada test as a preoperative evaluation. Twelve were tested with propofol and 55 were tested with amobarbital. Test conditions of the Wada test, recovery time of muscle power to manual muscle testing (MMT) Grade 3 (T3/5) and Grade 5 (T5/5), onset time of the first verbal response (Tverb) after injection and that of the first nonverbal response (Tnon-verb), were compared between the two groups. Power spectrum analysis of EEG background activity during the Wada test was performed and the time and spatial distribution of polymorphic slow activities were also compared in three cases. Results: With propofol injection, lateralities of language and memory function were identified in 12 and 9 of 12 patients in comparison to amobarbital (52 and 41 of 55 patients detection in language and memory function). No complications with direct intracarotid injection of propofol were observed. T3/5 and T5/5 with propofol injection were shorter while Tverb and Tnon-verb were longer compared to amobarbital. Absolute power of polymorphic slow EEG waves gradually increased and then rapidly decreased with propofol, which was in contrast to amobarbital injection. Conclusions: With direct intracarotid propofol injection, the Wada test was satisfactorily performed in all 12 patients and 2 more patients with left-handedness or with different injection dose for each side without any complications. Clinical usefulness of propofol as an alternative drug to amobarbital for the Wada test was indicated.
This method has been widely used to determine the hemisphere dominance of speech and memory 2 function and has become one of the most important preoperative evaluations in neurologic surgery. This technique requires a direct injection of short-acting anesthetic agents into the carotid artery for inducing transient anesthesia in unilateral hemisphere. Amobarbital has been commonly used for this purpose. Since 2001, amobarbital has not been available in Japan and scarcely available in other countries. Methohexital has some advantages over amobarbital and is used for the Wada test in many other countries, 3 but this agent is also not available in Japan. Thus, we were faced with the exigencies of searching for alternative agents. Using propofol anesthesia for the Wada test has been reported from countries in which amobarbital is unavailable. 4, 5 We sought to evaluate the usefulness of propofol as an alternative anesthetic agent to amobarbital for the Wada test through comparisons with our past data of the classic Wada test with amobarbital injection.
Part of the results of the present study was presented previously. 6, 7 Methods and materials. Subjects. A total of 123 patients (64 men and 59 women) underwent the Wada test as one of preoperative examinations. Sixty-seven patients who were right-handed and had the same injected dose on both sides for the Wada test were finally employed in this study. Handedness of these patients was assessed by the Edinburgh inventory revised in Japanese reference. 8 Fourteen patients underwent the Wada test with propofol and two patients were excluded from the final analysis because of left handedness in one and different dose of propofol injection between the left and right side in the other. However, for the analysis of potential adverse side effects, a total of 14 patients were employed. Informed consent was obtained from these 14 patients according to the Clinical Research Protocol No. 358 approved by the Committee of Medical Ethics, Kyoto University Graduate School of Medicine. Fifty-five patients underwent the Wada test with amobarbital from 1993 to 2001, and their records were retrospectively examined.
The procedure of the Wada test. Carotid catheterization was executed using a transfemoral approach, and cerebral angiography was performed prior to the Wada test. Before injection the patients were instructed to memorize two numbers and card designs to check their retrograde amnesia. Then they started counting backward from 100. When the patients counted to 90, the anesthetic agent was manually injected through the catheter over a period of approximately 5 seconds. The usual dose of propofol was 10 mg per 10 mL solution of saline. If 10 mg propofol did not produce a contralateral hemiplegia, additional propofol was injected immediately (the upper limit, 3 mg). In case of amobarbital, the usual dose was 100 mg per 10 mL solution of saline, and the added dose, if needed, was determined. The side suspected to contain the brain lesion was usually tested first.
The symptoms evaluated for language testing included blockage of counting (speech arrest), dysphasia, paraphasia, onset time of the first verbal response (Tverb) after injection and that of the first non-verbal response (Tnon-verb). Approximately 1 minute after injection, the test for memory registration was initiated. Four sets of memory items were presented. They included four objects and four abstract words shown for oral reading, one common object, two line-art diagrams, one color diagram to measure visual confrontation naming, and two other designs. Each item was presented visually at the beginning and then orally twice. The presentation sequence was identical in all patients. In interset intervals, patients were evaluated on the motor strength of their upper extremities by manual muscle testing 9 (MMT) by Medical Research Council. Patients' motor strength was estimated by the recovery time to motor Grade 3 (T3/5) and Grade 5 (T5/5) after the injection. Memory retention test usually began after the level of patient's consciousness and motor strength returned to baseline, usually 10 to 15 minutes after the injection. Free recall and choice-recognition memory were tested by using multiple choice with three foils per target item. Memory retention scores were the correct numbers of targets. The second injection into the contralateral hemisphere was performed about 20 to 50 minutes after the first injection. In all cases, the dosage of the second injection matched the first. One to several days before the Wada test, the pre-Wada memory test was performed. The dominant hemisphere for language and memory function was determined by these obtained scores compared between the two injections. If speech arrest or other language impairment (dysphasia, paraphasia) were observed immediately following drug injection into one hemisphere, then the injected side was judged to be dominant for language. 10, 11 If speech arrest or language impairment was observed following injections into both sides, the hemisphere with Tverb or Tnon-verb longer than 30 seconds was judged to be the dominant side. As for the dominant hemisphere of memory function, if the difference in the number of correctly recalled items from Wada memory test between two injections was between 6 and 14, the hemisphere producing the lower score by injection was judged to be dominant for memory function. If the difference in the numbers of correctly recalled items was between 2 and 5, then both hemispheres were judged to be related to memory function, although relatively more dominant on the side producing the lower score by injection. If the difference in the numbers was 0 or 1, then the memory function was judged to have no laterality. If poor memory score was revealed by pre-Wada memory test (less than 80%), the Wada test was considered as inconclusive. 12, 13 Power spectrum analysis (PSA). In two patients (Cases 1 and 2) who underwent Wada test with propofol and one patient (Case 3) with amobarbital, amplitude analysis of background EEG activity was performed. After angiography was completed, Cases 1 and 2 had carbon electrodes placed on the scalp according to the International 10-20 System and Case 3 had an electrode cap on which a total of 16 silver-coated silver-chloride electrodes were attached. Electrodes for recording electrooculogram were placed at the right upper and left lower outer canthi. The reference electrodes were placed on the bilateral ear lobes. All electrode impedance was kept below 5000 ohm. Time constants were set to 10 seconds for data acquisition. High frequency filters were set to 300 Hz when signals were sampled with 1,000 Hz (Cases 1 and 2), or set to 70 Hz when data were sampled with 200 Hz (Case 3).
EEG analysis was subsequently performed off-line. Data were divided into nine epochs (baseline, epoch 1-8). One data set from the raw-recording files is 120 seconds in duration for each epoch. Baseline data were obtained from the 2-minute period just before the injection, and then epoch 1 to 8 was continuously acquired. In Cases 1 and 2, these data sets were divided into 235 halfoverlapping 1.024 seconds long sections. For each data set free of artifacts, the Fast Fourier Transform was then calculated for each channel for consecutive 1.024 seconds sections (Hanning window, average of approximately 30 to 150 samples). 14 In Case 3, data sets were divided into 188 half-overlapping 1.277 seconds long sections.
Statistical analysis. Statistical analysis was done in patients' age (Student's t-tests), the type of lesion ( 2 test), other patients' profiles (sex and lesion side)
, and the Wada test's results (the degree of contralateral hemiplegia, retrograde amnesia, and laterality of function) (Fisher's exact probability test) between the two groups. With regard to recovery time of the language responses and motor strength, average and SD were calculated. Student's paired t-tests were also performed to compare the difference of recovery time for language response and motor strength between left and right injections in patients of each group and the recovery time of motor strength between the first and the second injections in the propofol group and Student's t-tests were performed to compare the difference of recovery time for language response and motor strength between the two drugs on both left and right side injection. All p values Ͻ 0.05 were considered significant.
Results. The demographic characteristics of the patients are shown in table 1. In 12 patients with propofol injection (7 men and 5 women), mean age at presentation was 39.5. Five patients had lesions in the left hemisphere, and five in the right. The remaining two patients had midline lesion each (aneurysm of basilar artery, brain tumor at the third ventricle). Three of the 12 patients were candidates for epilepsy surgery, 5 had brain tumors, and the remaining 4 had cerebral vascular disease. The average age of 55 patients given amobarbital (24 men and 31 women) was 37.0. Twenty-five patients given amobarbital had epileptogenic foci, lesions in the left hemisphere or both, and 30 in the right. Patients were referred to the clinic with three types of lesion: 26 from epilepsy, 21 from brain tumors, and 8 from cerebral vascular disease. There were no significant differences in the tested items of the patients' profiles (handedness, age, sex, lesion side, and type of lesion) between the two groups.
The Wada test. In 12 patients with propofol injection, the mean dose of injection was 11.0 mg, and the mean interval time between ipsi-and contralateral injections was 32.9 minutes. This condition produced 22 contralateral hemiplegias from 24 injections. Six patients of 22 showed retrograde amnesia. Propofol injection led to the conclusion with regard to the dominant hemisphere in language and memory function in 12 and 9 of 12 patients.
In 55 patients with amobarbital injection, the mean dosage was 104.0 mg, and the mean interval time was 33.0 minutes. Ninety-five contralateral hemiplegias occurred in 110 injections. Twenty-six out of 65 showed retrograde amnesia. Amobarbital injections concluded language and memory dominance in 52 and 41 of 55 patients (table 2) . No significant differences were present between the two groups in the occurrence rate of contralateral hemiplegia, retrograde amnesia, and laterality of function. Directly after administration of propofol, three patients exhibited some reactions that were comparatively rarely observed in the amobarbital Wada test: laughing in two patients with left side injection, head and eye version to the side to injection in two patients. After left side injection laughing continued for a few minutes in one patient, for approximately 5 minutes in the other patient. On the other hand, head and eye version occurred within 1 minute after injection and disappeared immediately. One of the excluded two patients showed face contortion and lacrimation. No persistent neurologic deficits or cardiopulmonary dysfunction appeared and no patients had vascular pain from direct arterial propofol injection. Table 3 shows the difference in recovery times for motor strength between the left and right injection. In each group, although recovery time of motor strength did not differ significantly between the sides of injection, recovery time of language response was significantly different. There were no significant differences in all recovery times (T3/5, T5/5) and all response times (Tverb, Tnon-verb) between the two drugs on both left and right side injection.
Case report of PSA. In three patients who underwent PSA, there was no angiographic interhemispheric crossflow. Prior to analysis, the absolute power of each channel was divided into six areas of scalp surface: for the left side injection, ipsilateral frontal (Fp1, F3, and F7), ipsilateral temporo-central (T3, T5, and C3), and ipsilateral parietooccipital (P3 and O1). Similar calculations were performed for the right side.
The figure, A and B , shows PSA data for the delta and theta bands in the cases of propofol injection on each side, 13 mg and 10 mg. In Case 1 (see the figure, A), absolute power of the delta band shows a gradual increase until epoch 3, 6 minutes after injection, and then a sharp decline to approximately baseline level in a few minutes. This effect was maximal in the ipsilateral frontal area. The contralateral frontal area was affected next while the ipsilateral temporocentral and parietooccipital areas were little affected. In Case 2 (see the figure, B), power change of the delta band also showed gradual increase and quick decrease. Owing to a large power value of frontal areas, the other areas were not outstanding, but changes in the ipsilateral temporocentral area were almost the same. With regard to theta activity, even its maximum amplitude was much smaller than that of delta and might be ignored. The figure, C, indicates data in a case with 100 mg amobarbital injection. Maximum activity of the delta and theta bands was attained at epoch 1 and smoothly decreased thereafter in all the ipsilateral areas and the contralateral frontal area. The absolute power change in each band, even though based on only a single case analysis, was in conformity with the previous reports, 15, 16 that is, the absolute power in delta and theta band reached the maximum in a few minutes after the injection and decreased smoothly in the following period. Unlike amobarbital behavior, effects of propofol injection on induction of polymorphic slow activity developed more gradually and diminished quickly.
Discussion. Two recent studies 4, 5 reported that the Wada test was carried out with intracarotid injection of propofol in the absence of any adverse effects. In Japan, propofol is available as an IV anesthetic agent. Propofol passes through the bloodbrain barrier and acts in the CNS. Its chemical structure is 2,6 di-isopropyl phenol. It is insoluble in water and is delivered to a target organ like an oil 
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Figure. Time course of absolute power change of delta and theta activities in two patients who had the Wada test using propofol (A, B) and one patient using amobarbital (C). A and B show the absolute power change from six scalp areas in delta and theta bands over a period of 18 minutes (from baseline to epoch 8) in patients who had injection of 13 (Case 1)
and 10 (Case 2) mg propofol. The absolute power of delta band increases gradually until epoch 3 (6 minutes after injection) maximally in the ipsilateral hemisphere and sharply decreased to the baseline levels in a few minutes. C shows the power change in a patient after 100 mg of amobarbital injection. Maximum power of the delta and theta bands was attained at epoch 1 (2 minutes after injection) and smoothly decreased thereafter in all the ipsilateral areas and also in the contralateral frontal area. ᭛ ϭ ipsi-frontal area; □ ϭ ipsi-temporocentral area; ϭ ipsi-parietooccipital area; X ϭ contra-frontal area; * ϭ contra-temporocentral area; ⅙ ϭ contra-parietooccipital area; baseline ϭ the 2-minute period just before the injection; EP1-EP8 ϭ the 2-minute period continuously acquired after the injection. solution. A solution of propofol is stable at pH value of 7.0 to 8.5 and its ratio of osmotic pressure to saline is approximately 1.0. The blood level of injected propofol reveals triphasic attenuation, and its halflife is 2.6, 51.0, and 365 minutes. The major side effects of propofol during IV injection include vascular pain and hypotension. Some studies reported that accidental injection of propofol into the artery of extremities caused vascular pain and transient hypesthesia of distal extremities as its side effects. [17] [18] [19] [20] [21] [22] [23] One study 24 reported a case of accidental injection of propofol into the aberrant radial artery. In the report, the patient was administered 140 mg of propofol and had pain in the hand. Then his hand became hyperemic, edematous and hyperaesthetic, lasting 24 hours. They attributed this case to inadvertent intraarterial propofol injection. In the majority of these case reports, however, the dose of accidental injection was approximately larger than the dosage usually used for introduction of general anesthesia. On the other hand, in both reports of the Wada test with propofol injection, doses of arterial injection were 20 mg/bolus. 4, 5 In their reports, patients described only the perception of an intense light blur or a hot sensation of the head but had no significant permanent deficits. In the present study, injection dosage was less than that used in any of the previous reports to avoid the eventual side effects as much as possible. An oil solution of propofol was dispensed in a concentration of 10 mg per 10 mL saline solution (0.1%). As for the physicochemical stability of the diluted solution of propofol, mixture with an oil solution of propofol and saline or 5% glucosic water shows no remarkable change in quality at a mixture ratio of 1:1, 1:2, 1:4, and 1:10 under room temperature up to 2 hours.
A previous case report 4 described the Wada test with 20 mg dose of propofol. The drug effect continued for 6 minutes and at that time polymorphic slow waveforms appeared on scalp EEG. They attributed the laterality of language dominance to speech disturbance caused as a drug effect. The opposite hemisphere, however, was not examined. Another study 5 reported a test with the same dose of propofol. The dose produced speech arrest for 2 minutes, followed by disturbances in language function and polymorphic slow activities on scalp EEG for 3 minutes. All symptoms produced by propofol recovered in 9 minutes. They examined the contralateral side by injecting the same dosage of propofol with intervals of 30 minutes. In the contralateral injection, the drug effect lasted for a total of 11 minutes, 2 minutes longer than that in the first injection. They emphasized that a lesser dose of propofol must be used in the second injection than in the first. The doses used, however, might be in excess for carrying out the procedure, and different doses between the first and second injections may lead to incorrect conclusion on the decision as for the dominant hemisphere. In our patients, the mean dose of 11.0 mg of propofol injection with a mean interval of 32.9 minutes was suffi-cient and adequate to produce the contralateral hemiplegia in almost all patients (22 of 24 injections), and it was as good as or even better than the results of amobarbital injection, as shown in table 2. In addition, T3/5 and T5/5 between the first and the second injection had no significant differences and during T5/5 we were able to finish the language and memory test, as shown (table 4) .
Hemispheric dominance for language and memory functions was successfully evaluated with propofol in almost all patients (12 and 9 of 12 patients) (see table 2 ). This score is by no means inferior to the score using amobarbital (52 and 41 of 55 patients). There were no significant differences in these scores between two groups by Fisher's exact probability test. The Wada test using propofol anesthesia has proven to be a valuable method for determining the hemispheric dominance of language and memory function. As for the adverse symptoms caused by intracarotid injection of propofol, three of 12 patients included in this study showed laughing, head and eye version immediately after the injection. These symptoms may reflect disinhibition of the frontal lobe function of the injected side, regardless of the injected anesthetic agents. One of two patients excluded in the statistical analysis showed ipsilateral face contortion and lacrimation immediately after the injection, although subjectively the patient had no discomfort. These symptoms quickly disappeared within a half minute. They can be caused by the vascular anastomosis or cross-filling of the peripheral vessels between the internal and external carotid system. Drug may affect the lacrimal grand and the facial muscles through the arterial shunt, if present, and it was immediately washed out from the target area. It is consistent with the short duration of the symptoms seen in one patient. These symptoms did not prevent the patients from completing the Wada test. In the present study, the intracarotid injection of approximately 10 mg of propofol has proven to be a reasonably safe method for the Wada test.
With regard to the difference of anesthetic effect between the two agents, in right handed patients, mean recovery time of motor strength was on the whole longer with amobarbital injection than with propofol injection (see table 3 ). In contrast, mean recovery time of language response from the left injection was on the whole longer with propofol injection than with amobarbital injection. On the other hand, PSA exhibited that the absolute power of polymorphic slow EEG activities with amobarbital injection rapidly increased and gradually decreased, while, with propofol injection, the power increased in a step-wise fashion and rapidly decreased (see the figure) . This behavior caused by propofol injection might suggest the possibility of less influence to the second injection compared with amobarbital injection. The inverse results of the two recovery times between the two agents might be caused by the different acting mechanism to the CNS. This study suggests that the Wada test using propofol could replace the traditional Wada test with amobarbital. However, because of the small number of subjects in this study, the optimal dosage of injection and the protocol of the Wada test need to be further refined.
